Survival and low-grade glioma: The emergence of genetic information

Neurosurgical Focus

Volumn 38, Issue 1, 2015, Pages

  Claus, Elizabeth B ^a,b   Walsh, Kyle M ^c   Wiencke, John K ^c   Molinaro, Annette M ^c   Wiemels, Joseph L ^c   Schildkraut, Joellen M ^d   Bondy, Melissa L ^e   Berger, Mitchel ^c   Jenkins, Robert ^f   Wrensch, Margaret ^c  

^a YALE UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Epidemiology; Genes; Glioma; GWAS; Low grade; SEER; Survival; Treatment

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BRAIN NEOPLASMS; CANCER GRADING; DISEASE FREE SURVIVAL; FEMALE; GENETICS; GLIOMA; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RISK; YOUNG ADULT;

EID: 84942501073     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.10.FOCUS12367     Document Type: Article

References (84)

1. Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, et al: Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 29:4430-4435, 2011
2. Bethke L, Sullivan K, Webb E, Murray A, Schoemaker M, Auvinen A, et al: The common D302H variant of CASP8 is associated with risk of glioma. Cancer Epidemiol Biomarkers Prev 17:987-989, 2008
3. Bethke L, Webb E, Murray A, Schoemaker M, Johansen C, Christensen HC, et al: Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma. Hum Mol Genet 17:800-805, 2008
4. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ: A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 64:1220-1223, 2004
5. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, et al: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715- 1721, 2003
6. Buckner JC, Pugh SL, Shaw EG, Gilbert MR, Barger G, Coons S, et al: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (Abstract)
7. Caggana M, Kilgallen J, Conroy JM, Wiencke JK, Kelsey KT, Miike R, et al: Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev 10:355-360, 2001
8. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al: Specific predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
9. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
10. Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich-Amiel A, Lejeune J, et al: Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology 67:872-874, 2006
11. Chen H, Chen Y, Zhao Y, Fan W, Zhou K, Liu Y, et al: Association of sequence variants on chromosomes 20, 11, and 5 (20q13.33, 11q23.3, and 5p15.33) with glioma susceptibility in a Chinese population. Am J Epidemiol 173:915-922, 2011
12. Claus EB, Black PM: Survival rates and patterns of care for patients diagnosed with supratentorial low grade gliomas: data from the SEER Program, 1973-2001. Cancer 106:1358- 1363, 2006
13. Claus EB, Horlacher A, Hsu L, Schwartz RB, Dello-Iacono D, Talos F, et al: Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 103:1227-1233, 2005
14. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al: A multigene predictor of outcome in glioblastoma. Neuro Oncol 12:49-57, 2010
15. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, et al: The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS ONE 5:e12548, 2010
16. Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE: Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86:321-327, 2008
17. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, et al: Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 13:2621-2626, 2007
18. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
19. De Roos AJ, Rothman N, Brown M, Bell DA, Pittman GS, Shapiro WR, et al: Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors. Neuro Oncol 8:145-155, 2006
20. De Roos AJ, Rothman N, Inskip PD, Linet MS, Shapiro WR, Selker RG, et al: Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev 12:14-22, 2003
21. Egan KM, Nabors LB, Olson JJ, Monteiro AN, Browning JE, Madden MH, et al: Rare TP53 genetic variant associated with glioma risk and outcome. J Med Genet 49:420-421, 2012
22. Egan KM, Thompson RC, Nabors LB, Olson JJ, Brat DJ, Larocca RV, et al: Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol 104:535-542, 2011
23. Everhard S, Kaloshi G, Crinière E, Benouaich-Amiel A, Lejeune J, Marie Y, et al: MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740-743, 2006
24. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, et al: Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64:6503-6510, 2004
25. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, et al: Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One 9:e91216, 2014
26. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, et al: Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17:4588-4599, 2011
27. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
28. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560-1566, 2010
29. Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Crinière E, et al: TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet 177:103-107, 2007
30. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, et al: Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in lowgrade gliomas. JAMA 308:1881-1888, 2012
31. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861, 2006
32. Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, Xiao Y, et al: Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet 204:13- 18, 2011
33. Jenkins RB, Xiao Y, Sicotte H, Decker PA, Kollmeyer TM, Hansen HM, et al: A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 44:1122-1125, 2012
34. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, et al: Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709-722, 2012
35. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, et al: Temozolomide for lowgrade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831-1836, 2007
36. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549-556, 1996
37. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, et al: Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330-337, 2009
38. Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, et al: Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). Eur J Cancer 34:1902-1909, 1998
39. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, et al: Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106:1759-1765, 2006
40. Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, Silva A, Amorim J, et al: TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet 180:14-19, 2008
41. Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, et al: Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol 11:59-68, 2009
42. Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, et al: Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol 28:2467-2474, 2010
43. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007
44. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al: IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-478, 2012
45. Mainio A, Tuunanen S, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci 256:516-521, 2006
46. Malmer B, Adatto P, Armstrong G, Barnholtz-Sloan J, Bernstein J, Claus EB, et al: GLIOGENE: An international effort for delineating the underlying causes of familial glioma. Cancer Epidemiol Biomarkers Prev 16:1730-1734, 2007
47. Malmer B, Feychting M, Lönn S, Ahlbom A, Henriksson R: p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev 14:2220-2223, 2005
48. Malmer BS, Feychting M, Lönn S, Lindström S, Grönberg H, Ahlbom A, et al: Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol 82:229-237, 2007
49. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, et al: Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65:1678-1686, 2005
50. Okcu MF, Selvan M, Wang LE, Stout L, Erana R, Airewele G, et al: Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 10:2618-2625, 2004
51. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
52. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173, 2006
53. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-2084, 2002
54. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, et al: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646-651, 2003
55. Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, Loeffler JS, et al: DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol 12:37-48, 2010
56. Rajaraman P, Stewart PA, Samet JM, Schwartz BS, Linet MS, Zahm SH, et al: Lead, genetic susceptibility, and risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev 15:2514-2520, 2006
57. Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, et al: Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev 16:1655-1661, 2007
58. Rice T, Zheng S, Decker PA, Walsh KM, Bracci P, Xiao Y, et al: Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro Oncol 15:535-541, 2013
59. Sanai N, Berger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753-766, 2008
60. Sanson M, Hosking FJ, Shete S, Zelenika D, Dobbins SE, Ma Y, et al: Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet 20:2897-2904, 2011
61. Schwartzbaum JA, Ahlbom A, Lönn S, Warholm M, Rannug A, Auvinen A, et al: An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol Biomarkers Prev 16:559-565, 2007
62. Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, et al: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/ Eastern Cooperative Oncology Group study. J Clin Oncol 120:2267-2276, 2002
63. Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, et al: Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 30:3065-3070, 2012
64. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al: Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41:899-904, 2009
65. Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, et al: Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. Cancer Res 71:7568-7575, 2011
66. Simon M, Hosking FJ, Marie Y, Gousias K, Boisselier B, Carpentier C, et al: Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res 16:5252- 5259, 2010
67. Simon M, Ludwig M, Fimmers R, Mahlberg R, Müller-Erkwoh A, Köster G, et al: Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme. Neurosurgery 59:1078-1085, 2006
68. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, et al: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103:802-809, 2005
69. Tang J, Shao W, Dorak MT, Li Y, Miike R, Lobashevsky E, et al: Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev 14:2040-2044, 2005
70. Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, et al: Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 89:179-185, 2008
71. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-483, 2012
72. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985-990, 2005
73. Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, et al: The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet 172:33-37, 2007
74. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
75. Verhaak RGW, Cooper LAD, Salama SS, Aldape K, Yung WKA, Brat DJ: AACR 2014: presentation abstract: comprehensive and integrative genomic characterization of diffuse lower grade gliomas. April 6, 2014. The Cancer Genome Atlas. (Abstract) (http://cancergenome.nih.gov/newsevents/ events/AACR2014_Abstract_LGGs) [Accessed November 18, 2014]
76. Walsh KM, Anderson E, Hansen HM, Decker PA, Kosel ML, Kollmeyer T, et al: Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. Genet Epidemiol 37:222-228, 2013
77. Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, et al: Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46:731-735, 2014
78. Wiencke JK, Aldape K, McMillan A, Wiemels J, Moghadassi M, Miike R, et al: Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev 14:1774-1783, 2005
79. Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, et al: Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 41:905-908, 2009
80. Wrensch M, McMillan A, Wiencke J, Wiemels J, Kelsey K, Patoka J, et al: Nonsynonymous coding single-nucleotide polymorphisms spanning the genome in relation to glioblastoma survival and age at diagnosis. Clin Cancer Res 13:197-205, 2007
81. Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, et al: Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 66:4531-4541, 2006
82. Xiao Y, Decker PA, Rice T, McCoy LS, Smirnov I, Patoka JS, et al: SSBP2 variants are associated with survival in glioblastoma patients. Clin Cancer Res 18:3154-3162, 2012
83. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
84. Yang P, Kollmeyer TM, Buckner K, Bamlet W, Ballman KV, Jenkins RB: Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. Cancer 103:2363-2372, 2005